e-Therapeutics (ETX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

9.60p
   
  • Change Today:
      0.43p
  • 52 Week High: 23.10
  • 52 Week Low: 8.13
  • Currency: UK Pounds
  • Shares Issued: 584.34m
  • Volume: 2,228,014
  • Market Cap: £56.10m

Deal with Barclays    Trade now with Barclays Stockbrokers

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (£m) Pre-tax (£m) EPS Dividend
31-Jul-23 Interim 0.16 (6.63) (0.97)p n/a

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Jan-19 0.04 (5.09) (1.49)p n/a n/a n/a n/a 0.0%
31-Jan-20 0.46 (2.87) (0.87)p n/a n/a n/a n/a 0.0%
31-Jan-21 0.32 (4.47) (0.99)p n/a n/a n/a n/a 0.0%
31-Jan-22 0.48 (9.52) (1.65)p n/a n/a n/a n/a 0.0%
31-Jan-23 0.47 (9.77) (1.54)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Jan-24 0.50 n/a (1.54)p n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest n/a n/a n/a 0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

e-Therapeutics Market Data

Currency UK Pounds
Share Price 9.60p
Change Today 0.43p
% Change 4.63 %
52 Week High 23.10
52 Week Low 8.13
Volume 2,228,014
Shares Issued 584.34m
Market Cap £56.10m

e-Therapeutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
21.37% below the market average21.37% below the market average21.37% below the market average21.37% below the market average21.37% below the market average
50.94% above the sector average50.94% above the sector average50.94% above the sector average50.94% above the sector average50.94% above the sector average
Price Trend
65.69% below the market average65.69% below the market average65.69% below the market average65.69% below the market average65.69% below the market average
19.30% above the sector average19.30% above the sector average19.30% above the sector average19.30% above the sector average19.30% above the sector average
Income Not Available
Growth
15.26% below the market average15.26% below the market average15.26% below the market average15.26% below the market average15.26% below the market average
24.32% below the sector average24.32% below the sector average24.32% below the sector average24.32% below the sector average24.32% below the sector average

e-Therapeutics Dividends

No dividends found

Trades for 25-Apr-2024

Time Volume / Share Price
10:05 560,000 @ 9.00p
16:15 30,000 @ 9.67p
16:06 50,000 @ 9.40p
16:06 65,677 @ 9.35p
15:26 3,761 @ 9.20p

e-Therapeutics Key Personnel

Chair Trevor Mervyn Jones
CEO Ali Mortazavi

Top of Page